Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Diamyd Medical ABDYMDF 41 Current Ratio is 15.50 as of May. 2026, which is 117% above its 10-year median of 7.14. GuruFocus rates DYMDF with a GF Score™ of 41/100 and a GF Value™ of $9.89. The stock has 3 warning signs investors should review. Among 1,405 Biotechnology companies, Diamyd Medical AB ranks better than 86.98% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Diamyd Medical AB's current ratio for the quarter that ended in May. 2026 was 15.50.
Diamyd Medical AB has a current ratio of 15.50. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for Diamyd Medical AB's Current Ratio or its related term are showing as below:
DYMDF'
s Current Ratio Range Over the Past 10 Years
Min: 1.53 Med: 7.14 Max: 16.48
Current: 15.5
During the past 13 years, Diamyd Medical AB's highest Current Ratio was 16.48. The lowest was 1.53. And the median was 7.14.
DYMDF's Current Ratio is ranked better than 86.98% of 1405
companies
in the Biotechnology industry
Industry Median: 3.83
vs DYMDF: 15.50
Diamyd Medical AB (OTCPK:DYMDF) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Diamyd Medical AB Current Ratio Related Terms
Diamyd Medical AB Current Ratio Historical Data
* Premium members only.
The historical data trend for Diamyd Medical AB's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DYMDF vs VRTX, REGN, RVMD: Current Ratio Comparison
For the Biotechnology subindustry, Diamyd Medical AB's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Diamyd Medical AB Current Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Diamyd Medical AB's Current Ratio distribution charts can be found below:
* The bar in red indicates where Diamyd Medical AB's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Diamyd Medical AB (DYMDF) has a Current Ratio of 15.50 as of May. 2026. This is 117% above median its historical median of 7.14. Over the past decade, Diamyd Medical AB's Current Ratio has ranged from 1.53 to 16.48. According to the industry distribution chart, Diamyd Medical AB ranks #183 out of 1405 companies in the Biotechnology industry, placing it in the top 13%.
Is Diamyd Medical AB's Current Ratio too high?
Diamyd Medical AB's current Current Ratio of 15.50 is 117% above median its 10-year median of 7.14. Over the past 10 years, this metric has ranged from a low of 1.53 to a high of 16.48. The Biotechnology industry median Current Ratio is 3.83. Diamyd Medical AB's value of 15.50 is 304.7% above this industry median. Based on the distribution chart, Diamyd Medical AB ranks #183 out of 1405 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Diamyd Medical AB has a GF Score™ of 41/100, reflecting its overall financial health beyond just this single metric.
How does Diamyd Medical AB's Current Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Diamyd Medical AB ranks #183 out of 1405 companies for Current Ratio. This places Diamyd Medical AB in the top 13% of its industry — outperforming the majority of peers. The industry median Current Ratio is 3.83. Diamyd Medical AB's value of 15.50 is 304.7% above this benchmark. Historically, Diamyd Medical AB's own Current Ratio has ranged from 1.53 to 16.48 over the past decade. While the company's 10-year median is 7.14 vs. the industry median of 3.83, Diamyd Medical AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Biotechnology company?
The median Current Ratio among Biotechnology companies is 3.83, based on 1,405 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Diamyd Medical AB's current Current Ratio of 15.50 is 304.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Current Ratio is 3.83 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Diamyd Medical AB's current Current Ratio is 15.50, which is 117% above median its own 10-year median of 7.14. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Diamyd Medical AB stock overvalued right now?
Diamyd Medical AB (DYMDF) has a current Current Ratio of 15.50. The stock's GF Value™ is $9.89, compared to a current price of $0.73 — trading 92.6% below its estimated fair value. The current Current Ratio is 15.50, which is 117% above median its 10-year median of 7.14 and 304.7% above the Biotechnology industry median of 3.83. Diamyd Medical AB's overall GF Score™ is 41/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Diamyd Medical AB (DYMDF), the current Current Ratio is 15.50 as of May. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Diamyd Medical AB (DYMDF) Overvalued in 2026?
Based on GuruFocus' analysis, Diamyd Medical AB stock appears to be undervalued.
The current stock price of $0.73 is trading 92.6% below its estimated GF Value™ of $9.89.
Key valuation signals for DYMDF:
Current Ratio: 15.50 (117% above median its 10-year median of 7.14)
GF Value™: $9.89 vs. price of $0.73 (92.6% below fair value)
Industry Position: 304.7% above the Biotechnology median (#183 of 1405)
No single metric tells the full story. See the DYMDF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Diamyd Medical AB develops precision medicine therapies for the prevention and treatment of type 1 diabetes using antigen-based immune technology. Its product candidate, Diamyd (rhGAD65/alum), is an antigen-specific immunomodulatory therapy that aims to preserve endogenous insulin production in individuals carrying the HLA DR3-DQ2 genotype and is being evaluated in the registrational Phase 3 DIAGNODE-3 trial in Stage 3 type 1 diabetes, as well as in the DiaPrecise trial in children with Stage 1 and Stage 2 type 1 diabetes. The Company's activities include clinical development, antigen-specific immunotherapy and in-house manufacturing of recombinant GAD65.
41GF Score
Get the complete analysis for DYMDF
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DYMDF has been successfully added to your 
